F2-isoprostanes in Alzheimer and other neurodegenerative diseases

Antioxidants and Redox Signaling

Volumn 7, Issue 1-2, 2005, Pages 269-275

  Montine, Thomas J ^a,e   Montine, Kathleen S ^a   McMahan, Wendy ^a   Markesbery, William R ^b   Quinn, Joseph F ^c   Morrow, Jason D ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; FREE RADICAL; ISOPROSTANE DERIVATIVE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL MODEL; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; HUMAN; LABORATORY DIAGNOSIS; LIPID PEROXIDATION; MOUSE; NEUROFIBRILLARY TANGLE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVIEW; URINE LEVEL; ANIMAL; BRAIN; CEREBROSPINAL FLUID; CHEMISTRY; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; TIME; URINE;

ANIMALIA;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BRAIN; CEREBROSPINAL FLUID; CHROMATOGRAPHY, GAS; F2-ISOPROSTANES; FREE RADICALS; HUMANS; LIPID PEROXIDATION; MASS SPECTROMETRY; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; TIME FACTORS;

EID: 13244271257     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.269     Document Type: Review

References (43)

1. Bohnstedt K, Karlberg B, Wahlund L, Jonhagen M, Basun H, and Schmidt S. Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 796: 11-19, 2003.
2. Butterfield D, Drake J, Pocernich C, and Castegna A. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7: 548-554, 2001.
3. Farber JL. Mechanisms of cell injury. In: Pathology of Environmental and Occupational Disease, edited by Craighead JE. St. Louis, MO: Mosby-Year Book Inc., 1995, pp. 287-302.
4. 2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med 27: 463-469, 1999.
5. Gutteridge JMC, Westermarck T, and Halliwell B. Oxygen radical damage in biological systems. In: Free Radicals, Aging, and Degenerative Diseases, edited by Johnson JE, Walford R, Harman D, and Miquel J. New York: Alan R. Liss, 1986, pp. 99-139.
6. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, and Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-102, 1996.
7. Sw transgenic mice develop age-related A deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965-973, 1997.
8. Lovell M, Ehmann W, Butler S, and Markesbery W. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45: 1594-1601, 1995.
9. Lovell M, Ehmann W, Mattson M, and Markesbery W. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-471, 1997.
10. Lovell MA, Xie C, and Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22: 187-194, 2001.
11. Mark RJ, Lovell MA, Markesbery WR, Uchida K, and Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68: 255-264, 1997.
12. Markesbery WR and Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36, 1998.
13. Mattson MP. Modification of ion homeostasis by lipid peroxidation: roles in neuronal degeneration and adaptive plasticity. Trends Neurosci 20: 53-57, 1998.
14. 2-isoprostanes are increased in Alzheimer's disease. Ann Neurol 44: 410-413, 1998.
15. 2-isoprostane concentration in probable Alzheimer's disease. Neurology 52: 562-565, 1999.
16. 2-isoprostanes are elevated in Huntington's disease. Neurology 52: 1104-1105, 1999.
17. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ, and Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles, or with APOE genotype in Alzheimer's disease patients. Am J Pathol 155: 863-868, 1999.
18. 2 levels in patients with probable Alzheimer's disease. Neurology 53: 1495-1498, 1999.
19. 2-isoprostanes among patients with Huntington's disease or Alzheimer's disease, and controls. Ann Neurol 48: 950, 2000.
20. 42, tau, and F2-isoprostane concentrations in patients with Alzheimer's disease, other dementias, and age-matched controls. Arch Pathol Lab Med 125: 510-512, 2001.
21. 4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52: 175-179, 2002.
22. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, and Morrow JD. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 33: 620-626, 2002.
23. 2- isoprostanes as biomarkers of Alzheimer's disease. Submitted.
24. Moore K and Roberts LJ. Measurement of lipid peroxidation. Free Radic Res 28: 659-671, 1998.
25. 2-like compounds produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc Natl Acad Sci U S A 87: 9383-9387, 1990.
26. 2-isoprostanes produced by non-cyclooxygenase free radical catalyzed mechanism. Methods Enzymol 233: 163-174, 1994.
27. Picklo MJ, Olson SJ, Markesbery WR, and Montine TJ. Expression and activities of aldoketo oxidoreductases in Alzheimer's disease. J Neuropathol Exp Neurol 60: 686-695, 2001.
28. Porter NA, Caldwell SE, and Mills KA. Mechanisms of free radical oxidation of unsaturated lipids. Lipids 30: 277-290, 1995.
29. 2α-I - an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A 95: 3449-3454, 1998.
30. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12: 1777-1784, 1998.
31. 2α-IV in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48: 809-812, 2000.
32. Pratico D, Uryu K, Leight S, Trojanowski JQ, and Lee VM. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21: 4183-4187, 2001.
33. Pratico D, Clark CM, Liun F, Lee VY-M, and Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch Neurol 59: 972-976, 2002.
34. Pulliam J, Jennings C, Kryscio R, Davis D, Wilson D, Montine T, Schmitt F, and Markesbery W. Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation with APOE. Am J Med Genet 118B: 48-53, 2003.
35. Quinn J, Montine TJ, Morrow JD, Woodward WR, Kulhanek D, and Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 137: 32-41, 2003.
36. Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, and Montine TJ. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J Alzheimers Dis 6: 93-97, 2004.
37. Reich E, Markesbery W, Roberts L 2nd, Swift L, Morrow J, and Montine T. Brain regional quantification of F-ring and D/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 158: 293-297, 2001.
38. Selley ML. 4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 25: 169-174, 1998.
39. Sidell KR, Olson SJ, Ou JJ, Zhang Y, Amarnath V, and Montine TJ. Cysteine and mercapturate conjugates of oxidized dopamine are in human striatum but only the cysteine conjugate impedes dopamine trafficking in vitro and in vivo. J Neurochem 79: 510-521, 2001.
40. Sidell KR, Montine KS, Picklo MJ, Olson SJ, Amarnath V, and Montine TJ. Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrum. J Neuropathol Exp Neurol 162: 146-153, 2003.
41. Tuppo EE, Forman LJ, Spur BW, Chan-Ting RE, Chopra A, and Cavalieri TA. Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Res Bull 54: 565-568, 2001.
42. 2-isoprostane levels are increased in Alzheimer's disease: evidence of increased oxidative stress in vivo. Alzheimers Rep 2: 277-282, 1999.
43. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC, Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61: 82-88, 2004.